Long-Term Fosfomycin-Tromethamine Oral Therapy for Difficult-To-Treat Chronic Bacterial Prostatitis

Ibai Los-Arcos, Carles Pigrau, Dolors Rodríguez-Pardo, Nuria Fernández-Hidalgo, Antonia Andreu, Nieves Larrosa, Benito Almirantea

    Research output: Contribution to journalArticleResearchpeer-review

    24 Citations (Scopus)


    © 2016, American Society for Microbiology. All Rights Reserved. This is a retrospective study of 15 difficult-to-treat (i.e., exhibiting previous failure, patient side effects, or resistance to ciprofloxacin and co-trimoxazole) chronic bacterial prostatitis infections (5 patients with multidrug-resistant Enterobacteriaceae [MDRE]) receiving fosfomycin-tromethamine at a dose of 3 g per 48 to 72 h for 6 weeks. After a median follow-up of 20 months, 7 patients (47%) had a clinical response, and 8 patients (53%) had persistent microbiological eradication; 4/5 patients with MDRE isolates achieved eradication. There were no side effects. Fosfomycin-tromethamine is a possible alternative therapy for chronic bacterial prostatitis.
    Original languageEnglish
    Pages (from-to)1854-1858
    JournalAntimicrobial Agents and Chemotherapy
    Issue number3
    Publication statusPublished - 1 Mar 2016


    Dive into the research topics of 'Long-Term Fosfomycin-Tromethamine Oral Therapy for Difficult-To-Treat Chronic Bacterial Prostatitis'. Together they form a unique fingerprint.

    Cite this